On March 29th, at the American College of Cardiology (ACC) 2025 meeting, Novo Nordisk announced that the results of the STRIDE Phase III trial had reached the primary endpoint. The test showed that, compared with the placebo group, the maximum walking distance of patients with type II diabetes combined with peripheral artery disease in the steep slope walking test increased by 13% after 52 weeks of Ozempic (1.0 mg Smeglutide was injected once a week). The research results were simultaneously published in the journal The Lancet.
Scan code to share